Investor Relations

Company Overview

We aspire to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Our experienced team brings significant breadth and depth of expertise in drug development, combined with a commitment to develop new treatments for women suffering from uterine fibroids, endometriosis, and infertility, and men suffering from prostate cancer.

We are advancing programs in women’s health, including heavy menstrual bleeding associated with uterine fibroids, endometriosis-associated pain, and egg maturation in assisted reproduction, including in vitro fertilization (IVF).

Over time, we intend to expand our development pipeline to include potential treatments for women's health.

FDA Approved Drugs: ORGOVYX (relugolix 120 mg)

Copyright West LLC. Share price minimum 15 minutes delayed. Market cap from previous market close.

Press Releases
April 12, 2021
Myovant Sciences and Pfizer Announce First Participant Dosed in Phase 3 SERENE Study Evaluating Contraceptive Efficacy of Once-Daily Relugolix Combination Tablet
April 5, 2021
Myovant Sciences Appoints Lauren Merendino as Chief Commercial Officer
March 29, 2021
Myovant Sciences Announces European Medicines Agency Validation of Marketing Authorization Application for Relugolix for the Treatment of Advanced Prostate Cancer
Events

SEC Filings

Filing date Description Form View

Annual report which provides a comprehensive overview of the company for the past year

10-K View HTML EX-101.INS - XBRL INSTANCE DOCUMENT

Annual report which provides a comprehensive overview of the company for the past year

10-K View HTML EX-101.INS - XBRL INSTANCE DOCUMENT